Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Toronto Stock Exchange  >  Tekmira Pharmaceuticals Corporation    TKM   CA87911B2093

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Tekmira Pharmaceuticals Corporation : Tekmira to License Technology to Monsanto for Weed Control Research

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/13/2014 | 03:00pm CET
By Everdeen Mason 

Tekmira Pharmaceuticals Corp. agreed to allow agriculture business Monsanto Co. to license use of its proprietary delivery technology, a deal Tekmira says is worth up to $86.2 million.

Tekmira shares shot up 33% in premarket trading following the deal's announcement.

Tekmira, which focuses on RNA interference therapeutics, will provide lipid formulations to Monsanto, which will be used for the latter company's research on new pest, virus and weed control options for agriculture.

The option agreement between the two companies will last four years, and Monsanto will pay Tekmira an option exercise fee for the exclusive right use Tekmira's technology in agriculture. Tekmira said it expects a near term payment of $16.5 million.

Monsanto, which is the largest seed company by sales, has benefited from a long-running farm boom in the U.S. and South America driven by high prices for corn and other commodities.

Write to Everdeen Mason at everdeen.mason@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TEKMIRA PHARMACEUTICALS CO
11/16 Arbutus’ LNP Licensee Alnylam Initiates Rolling Submission of New Drug ..
11/13 Arbutus’ LNP Licensee Alnylam Receives Accelerated Assessment of Patisi..
11/02 Arbutus Announces Corporate Update and Third Quarter 2017 Financial Results
11/02 ARBUTUS BIOPHARMA CORP : Arbutus Biopharma Corporation to Host Earnings Call
10/31 Arbutus Announces Conference Call to Provide a Corporate Update and Third Qua..
10/24 Arbutus Presents HBV Data at 2017 AASLD Liver Meeting
10/18 Gritstone Oncology and Arbutus Biopharma Announce LNP Technology Licensing Ag..
10/16 Arbutus Announces Closing of $50 Million First Tranche of $116.4 Million Stra..
10/10 Arbutus to Participate in Upcoming Investor Conferences
10/03 Arbutus to Present HBV Data at 2017 AASLD Liver Meeting
More news
News from SeekingAlpha
2015 WHO approves rapid test for Ebola
2015 BIOTECH STOCKS : What's Hot, What's Not - As Seen By Market-Makers, Their Client..
2015 U.S. to pull troops from Ebola zone
2015 SEEKING ALPHA'S BIOTECH WEEKLY : Questioning Gilead, MannKind To Market, And Mor..
2015 TEKMIRA : Bad Idea Genes
Financials ($)
Sales 2017 6,29 M
EBIT 2017 -71,7 M
Net income 2017 -69,8 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 51,2x
Capi. / Sales 2018 68,3x
Capitalization 322 M
Chart TEKMIRA PHARMACEUTICALS CO
Duration : Period :
Tekmira Pharmaceuticals Co Technical Analysis Chart | TKM | CA87911B2093 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 9,21 $
Spread / Average Target 57%
EPS Revisions
Managers
NameTitle
Mark J. Murray President, Chief Executive Officer & Director
Vivek Ramaswamy Chairman
Bruce G. Cousins Chief Financial Officer & Executive Vice President
Peter Lutwyche Chief Technology Officer
Michael J. Sofia Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
TEKMIRA PHARMACEUTICALS CORPORATION0.00%322
CELLTRION, INC.--.--%24 331
IQVIA HOLDINGS INC37.23%21 966
INCYTE CORPORATION-1.32%20 893
LONZA GROUP62.21%19 860
ALNYLAM PHARMACEUTICALS, INC.252.59%13 012